IQAI - Ticker AI Digest

IQ-AI Ltd 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (IQAI) 1
IQAI 13:24
IQ-AI Ltd
Result of AGM
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
IQAI 06:30
IQ-AI Ltd
Application: FDA Breakthrough Therapy Designation
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Imaging Biometrics, a subsidiary of IQ-AI Limited, has applied to the US FDA for Breakthrough Therapy Designation for its oral gallium maltolate (GaM) therapy. The therapy is intended to treat adult patients with recurrent or refractory glioblastoma, a form of brain cancer. Preliminary findings from the Phase 1 trial show promising results, with a reported overall survival rate of 34.1 months, significantly higher than the current median survival rate. The Breakthrough Therapy Designation, if granted, would provide additional FDA support and guidance, building upon the Fast Track Designation already received. The application reflects the companys optimism about the potential of oral GaM as an effective treatment for glioblastoma.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
IQAI 12:47
IQ-AI Ltd
Publication of Annual Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
IQ-AI Limited, a company listed on the London Stock Exchange, has released its audited financial statements for the year ended December 31, 2024. The companys revenue grew by over 20% in 2024, reaching $959k (£750k), and financial results improved significantly with losses halved compared to 2023. The companys umbrella product, IB Clinic, is expanding in use and application, and it has secured GE Healthcare as a sales partner. Post-year, the company raised £250k in funds.
The companys focus areas include IB Clinic, with its various software platforms for MR DSC perfusion processing, whole-body blood flow analysis, and kidney stone and liver health assessment
IB Zero G, a technology to eliminate the need for contrast agents in imaging, which is still in early development
IB Nimblea telemedicine platform
and IB003, a Phase 1 clinical trial drug candidate for glioblastoma.
The company plans to change its name to Imaging Biometrics Limited to reflect its sole operating subsidiary. The directors share the frustration of shareholders regarding the companys market valuation and believe it has huge potential. The company has no debt and a large bank of IP, and directors believe it can achieve profitability in the near future.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 4
IQAI 13:24
IQ-AI Ltd
Result of AGM
IQAI 06:30
IQ-AI Ltd
Application: FDA Breakthrough Therapy Designation
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Imaging Biometrics, a subsidiary of IQ-AI Limited, has applied to the US FDA for Breakthrough Therapy Designation for its oral gallium maltolate (GaM) therapy. The therapy is intended to treat adult patients with recurrent or refractory glioblastoma, a form of brain cancer. Preliminary findings from the Phase 1 trial show promising results, with a reported overall survival rate of 34.1 months, significantly higher than the current median survival rate. The Breakthrough Therapy Designation, if granted, would provide additional FDA support and guidance, building upon the Fast Track Designation already received. The application reflects the companys optimism about the potential of oral GaM as an effective treatment for glioblastoma.
IQAI 09:50
IQ-AI Ltd
Notice of AGM
IQAI 12:47
IQ-AI Ltd
Publication of Annual Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
IQ-AI Limited, a company listed on the London Stock Exchange, has released its audited financial statements for the year ended December 31, 2024. The companys revenue grew by over 20% in 2024, reaching $959k (£750k), and financial results improved significantly with losses halved compared to 2023. The companys umbrella product, IB Clinic, is expanding in use and application, and it has secured GE Healthcare as a sales partner. Post-year, the company raised £250k in funds.
The companys focus areas include IB Clinic, with its various software platforms for MR DSC perfusion processing, whole-body blood flow analysis, and kidney stone and liver health assessment
IB Zero G, a technology to eliminate the need for contrast agents in imaging, which is still in early development
IB Nimblea telemedicine platform
and IB003, a Phase 1 clinical trial drug candidate for glioblastoma.
The company plans to change its name to Imaging Biometrics Limited to reflect its sole operating subsidiary. The directors share the frustration of shareholders regarding the companys market valuation and believe it has huge potential. The company has no debt and a large bank of IP, and directors believe it can achieve profitability in the near future.

AI Crunch

Single-Ticker AI Crunch
IQAI signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for IQ-AI Ltd. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full IQAI AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for IQAI on 2025-05-22.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
2035357
Enterprise Value
2979250
Public Float
62.29
Broker Target
63.25
Shares Out
246710000
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
JE00BD4H0R42
Market
LSE - MAIN MARKET
Sector
Health Care Providers
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2011-04-06
Earnings Date
-
Net Debt
-53500.0
Cash
53500.0
EPS
-
Net Income
-327103.0
Revenue
750105.0
Enterprise Value
2979250
Trailing PE
-
Forward PE
-
Price Sales TTM
2.7134
Price Book MRQ
5.8716
EV Revenue
2.1831
EV EBITDA
-9.2047

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
-
Institutions As Of
2024-10-14
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
1
Purchase TR1
1
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit IQAI.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-05-22 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
IQ-AI Ltd has fresh news flow feeding the chart narrative.
13:24 Today's Catalyst Result of AGM
AI Charts Studio
IQAI Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-05-22 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast